Three years after Teva Pharmaceutical Industries ($TEVA) and Switzerland's Lonza joined forces to develop a few blockbuster biosimilars, one of their lead programs has hit an unexpected roadblock. The Israeli newspaper Haaretz reports that Teva has suspended its Phase III study of a biosimilar of Rituxan, one of the world's top-selling drugs from Roche ($RHHBY). Report